Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Registry of Toxic Effects of Chemical Substances (RTECS)

2,6-Octadienal, 3,7-dimethyl-

RTECS #

RG5075000

CAS #

5392-40-5

Updated

October 2017

Molecular Weight

152.26

Molecular Formula

C10H16O

Synonyms

3,7-Dimethyl-2,6-octadienal
Citral
Lemsyn GB
NCI-C56348

Skin and Eye Irritation and References

Route/OrganismDoseEffectReference
skin /guinea pig 1%/48H moderateJSCCA5 28,357,1977
skin /guinea pig 100 mg/24H severeCTOIDG 94(8),41,1979
skin /human 2%/2DCODEDG 61,217,2009
skin /human 40 mg/24H mildFCTXAV 17,259,1979
skin /man 16 mg/48H severeCTOIDG 94(8),41,1979
skin /pig 50 mg/48H severeCTOIDG 94(8),41,1979
skin /rabbit 500 mg/24H moderateFCTXAV 17,259,1979
skin /rabbit 100 mg/24H severeCTOIDG 94(8),41,1979
skin /woman 2%CODEDG 57,125,2007

Mutation Data and Reference

System TestRoute/Organism/TissueDoseReference
DNA Damagelymphocyte/human25 mg/L/3HFCTOD7 68,71,2014
DNA repair/Bacillus subtilis2222 µg/discOIGZDE 34,267,1985

Reproductive Effects Data and References

Route/OrganismDoseEffectReference
inhalation/rat 85 ppm (6-15D pregnant)Reproductive: Other effects on femaleHPV396 -,-,2001
intraperitoneal/rat 1800 mg/kg (22W prior to copulation)Reproductive: Maternal effects: Oogenesis

Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea)

Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)
FCTXAV 18,547,1980
intraperitoneal/rat 1800 mg/kg (6D prior to copulation)Reproductive: Maternal effects: Ovaries, fallopian tubes

Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth)
JRPFA4 55,347,1979
intraperitoneal/rat 1800 mg/kg (6D prior to copulation)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on newborn: Other postnatal measures or effects
VCVPS* -,286,1998
oral/rat 9120 mg/kg (14D pre-21D after birth)Reproductive: Other effects on femaleHPV396 -,-,2001
oral/rat 28500 mg/kg (14D pre-21D after birth)Reproductive: Other effects on female

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)
HPV396 -,-,2001
oral/rat 600 mg/kg (6-15D pregnant)Reproductive: Other effects on female

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)
HPV396 -,-,2001
oral/rat 1250 mg/kg (6-15D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)TXCYAC 96,105,1995
oral/rat 2500 mg/kg (6-15D pregnant)Reproductive: Effects on fertility: Female fertility index (e.g., # females pregnant per # sperm positive females; # females pregnant per # females mated)

Reproductive: Other developmental abnormalities
TXCYAC 96,105,1995
oral/rat 10 gm/kg (6-15D pregnant)Reproductive: Other effects on female

Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea)

Reproductive: Effects on embryo or fetus: Fetal death
TXCYAC 96,105,1995
oral/rat 10 gm/kg (6-15D pregnant)Reproductive: Specific developmental abnormalities: Musculoskeletal system

Reproductive: Effects on newborn: Sex ratio
TXCYAC 96,105,1995
skin/rat 28 gm/kg (60D prior to copulation)Reproductive: Maternal effects: Oogenesis

Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea)

Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)
FCTXAV 18,547,1980
skin/rat 46 gm/kg (14W prior to copulation)Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive)FCTXAV 18,547,1980
skin/rat 46 gm/kg (14W prior to copulation)Reproductive: Maternal effects: Ovaries, fallopian tubes

Reproductive: Effects on fertility: Other measures of fertility

Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive)
JRPFA4 55,347,1979
skin/rat 27600 mg/kg (60D prior to copulation)Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth)JRPFA4 55,347,1979
skin/rat 27.6 gm/kg (60D prior to copulation)Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on newborn: Other postnatal measures or effects
VCVPS* -,286,1998

Acute Toxicity Data and References

Route/OrganismDoseEffectReference
In Vitro/Hamster, ovary Inhibitor Concentration (50 percent kill): 20.62 mg/LIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.JOETD7 151,652,2014
In Vitro/Human, fibroblast Inhibitor Concentration (50 percent kill): 39.48 mg/LIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.JOETD7 151,652,2014
In Vitro/Human, leukemia cells Inhibitor Concentration (25 percent kill): 24.0 mg/L/24HIn Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.TIVIEQ 26,1150,2012
In Vitro/Human, leukemia cells Inhibitor Concentration (50 percent kill): 8.41 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 26,1150,2012
In Vitro/Human, leukemia cells Inhibitor Concentration (5 percent kill): 185 mg/L/30MIn Vitro Toxicity Studies: Cell countingTIVIEQ 27,857,2013
In Vitro/Human, leukemia cells Inhibitor Concentration Low: 35.6 mg/L/30MIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,857,2013
In Vitro/Human, monocyte Inhibitor Concentration Low: 62.2 mg/L/2HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1233,2013
In Vitro/Human, skin Inhibitor Concentration Low: 50 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TXAPA9 283,147,2015
In Vitro/Human, skin Inhibitor Concentration Low: 10 µmol/L/24HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationTXAPA9 283,147,2015
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 4.45 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1127,2013
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 20 mg/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,1127,2013
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 182.8 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TXAPA9 245,281,2010
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 23.2 µmol/L/48HIn Vitro Toxicity Studies: Other assaysTXAPA9 245,281,2010
In Vitro/Human, skin Inhibitor Concentration (20 percent kill): 34.3 mg/L/21HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,314,2013
In Vitro/Human, skin Inhibitor Concentration Low: 34.3 mg/L/4HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,314,2013
In Vitro/jpcInhibitor Concentration Low: 100 µg/mL/3HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.FCTOD7 68,71,2014
In Vitro/jpcInhibitor Concentration Low: 200 µg/mL/3HIn Vitro Toxicity Studies: Apoptosis in vitroFCTOD7 68,71,2014
In Vitro/jrdInhibitor Concentration (50 percent kill): 4.78 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 28,626,2014
In Vitro/Mouse, macrophage Inhibitor Concentration Low: 5 µg/wellIn Vitro Toxicity Studies: Other assaysJOETD7 137,909,2011
In Vitro/mraInhibitor Concentration (25 percent kill): 4.9 mg/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TOLED5 216,65,2013
In Vitro/mraInhibitor Concentration Low: 0.49 mg/L/24HBiochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammationTOLED5 216,65,2013
In Vitro/praInhibitor Concentration (50 percent kill): 20.1 ppm/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,1220,2013
In Vitro/praInhibitor Concentration (50 percent kill): 1.1 ppm/48HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1220,2013
intraperitoneal/mouse lowest published toxic dose: 50 mg/kgBehavioral: Alteration of classical conditioningPYTOEY 9,709,2002
intraperitoneal/mouse lowest published toxic dose: 200 mg/kgBehavioral: Change in motor activity (specific assay)

Behavioral: Muscle weakness

Behavioral: Alteration of classical conditioning
PYTOEY 9,709,2002
intraperitoneal/rat lethal dose (50 percent kill): 460 mg/kgJRPFA4 55,347,1979
oral/mouse lethal dose (50 percent kill): 6 gm/kgTumorigenic: Active as anti-cancer agentBIJOAK 34,1196,1940
oral/mouse lethal dose (50 percent kill): 1.67 gm/kgVCVPS* -,291,1998
oral/rat lethal dose (50 percent kill): 3.45 gm/kgLiver: Changes in liver weight

Kidney, Ureter, and Bladder: Changes in kidney weight
VCVPS* -,291,1998
oral/rat lethal dose (50 percent kill): 4960 mg/kgBehavioral: Somnolence (general depressed activity)HPV396 -,-,2001
skin/rabbit lethal dose (50 percent kill): 2250 mg/kgFCTOD7 25,505,1987
subcutaneous/rat lowest published toxic dose: 34.5 mg/kgImmunological Including Allergic: Increase in cellular immune responseFCTOD7 45,1516,2007

Other Multiple Dose Data and References

Route/OrganismDoseEffectReference
intraperitoneal/rat lowest published toxic dose: 1800 mg/kg/6D- intermittentReproductive: Maternal effects: Ovaries, fallopian tubes

Related to Chronic Data: Changes in ovarian weight
VCVPS* -,291,1998
intraperitoneal/rat lowest published toxic dose: 0.7 mg/kg/7D- intermittentBrain and Coverings: Other degenerative changes

Behavioral: Alteration of operant conditioning

Biochemical: Metabolism (intermediary): Other
PBBHAU 93,391,2009
oral/mouse lowest published toxic dose: 14952 mg/kg/14D- intermittentLiver: Other changes

Liver: Changes in liver weight

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
FCTOD7 31,463,1993
oral/rabbit lowest published toxic dose: 255 mg/kg/13W- intermittentKidney, Ureter, and Bladder: Interstitial nephritis

Kidney, Ureter, and Bladder: Proteinuria

Blood: Other changes
FAONAU 44A,1,1967
oral/rat lowest published toxic dose: 24 gm/kg/10D- intermittentLiver: Changes in liver weight

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)

Biochemical: Effect on specific coenzyme: CoA
FCTOD7 25,505,1987
skin/mouse lowest published toxic dose: 525 mg/kg/3D- intermittentImmunological Including Allergic: Increase in cellular immune response

Immunological Including Allergic: Increase in humoral response
TXCYAC 206,285,2005
skin/rat lowest published toxic dose: 5550 mg/kg/30D- intermittentEndocrine: Other changesCBPCEE 115,169,1996
skin/rat lowest published toxic dose: 27.6 gm/kg/60D- intermittentReproductive: Maternal effects: Ovaries, fallopian tubes

Related to Chronic Data: Changes in ovarian weight
VCVPS* -,291,1998
skin/rat lowest published toxic dose: 12648 mg/kg/17W- intermittentSkin: After systemic exposure: Dermatitis, other

Skin and Appendages: Other: Hair
URLRA5 20,139,1992
skin/rat lowest published toxic dose: 3720 mg/kg/5W- intermittentReproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glandsURLRA5 20,139,1992

Reviews

OrganizationStandardReference
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-time-weighted average 5 ppm (inhal, vapor, skin, sen)DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-Not classifiable as a human carcinogenDTLVS* TLV/BEI,2013
TOXICOLOGY REVIEWMUREAV 659,248,2008
TOXICOLOGY REVIEWMUREAV 566,49,2004
TOXICOLOGY REVIEWTXAPA9 250,87,2011
TOXICOLOGY REVIEWFCTOD7 81,9,2015
TOXICOLOGY REVIEWFCTOD7 92,150,2016

NIOSH Documentation and Surveillance

OrganizationStandardReference
National Occupational Exposure Survey 1983Hazard Code 83184; Number of Industries 98; Total Number of Facilities 12505; Number of Occupations 84; Total Number of Employees Exposed 200484; Total Number of Female Employees Exposed 83180
National Occupational Hazard Survey 1974Hazard Code 83184; Number of Industries 5; Total Number of Facilities 353; Number of Occupations 33; Total Number of Employees Exposed 68051

Status in Federal Agencies

OrganizationReference
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA Section 8(e) Risk Notification, 8EHQ-0892-9204
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (feed);equivocal evidence:mouse
NCI Carcinogenesis Studies (feed);no evidence:rat
NTP Carcinogenesis studies; test completed (peer review), October 2000
TOP